Prothena Corp (PRTA) Ph1 Results Show Slowing of Neuropathy Progression, Oppenheimer Raises PT to $25

December 10, 2020 6:47 AM

Oppenheimer analyst Jay Olson reiterated an Outperform rating and raised the price target to $25.00 (from $20.00) on Prothena Corp ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found